2025-522635-34-00CompletedPhase 1
A Study to Evaluate the Effect of TRIV-509 on Skin Barrier Function in Patients with Atopic Dermatitis.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Jan 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 18 Aug 2025
- Start date
- 9 Oct 2025
- Lead sponsor
- Triveni Bio Inc.
- Diseases
- Atopic dermatitis (eczema)
- EU CT number
- 2025-522635-34-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.